The estimated Net Worth of Jantrill Ab Stahlberg is at least $22.9 Millón dollars as of 28 June 2024. Jantrill Stahlberg owns over 1,200,000 units of DiaMedica Therapeutics stock worth over $22,870,643 and over the last few years Jantrill sold DMAC stock worth over $0.
Jantrill has made over 1 trades of the DiaMedica Therapeutics stock since 2024, according to the Form 4 filled with the SEC. Most recently Jantrill bought 1,200,000 units of DMAC stock worth $3,000,000 on 28 June 2024.
The largest trade Jantrill's ever made was buying 1,200,000 units of DiaMedica Therapeutics stock on 28 June 2024 worth over $3,000,000. On average, Jantrill trades about 1,200,000 units every 0 days since 2024. As of 28 June 2024 Jantrill still owns at least 5,221,608 units of DiaMedica Therapeutics stock.
You can see the complete history of Jantrill Stahlberg stock trades at the bottom of the page.
Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg y David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics executives and other stock owners filed with the SEC include: